Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers, LLP
mi
from
Denver, CO
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers, LLP
mi
from
Denver, CO
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers
mi
from
Denver, CO
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers
mi
from
Denver, CO
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers
mi
from
Lakewood, CO
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers
mi
from
Lakewood, CO
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers
mi
from
Littleton, CO
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers
mi
from
Littleton, CO
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers
mi
from
Lone Tree, CO
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers
mi
from
Longmont, CO
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers
mi
from
Longmont, CO
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers
mi
from
Parker, CO
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers
mi
from
Parker, CO
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers
mi
from
Thornton, CO
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers
mi
from
Thornton, CO
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Georgetown University Hospital Lombardi Cancer Center
mi
from
Washington,
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Georgetown University Hospital Lombardi Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Georgetown University Medical Center
mi
from
Washington,
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
mi
from
Bonita Springs, FL
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
mi
from
Bonita Springs, FL
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
mi
from
Bradenton, FL
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
mi
from
Bradenton, FL
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
mi
from
Cape Coral, FL
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
mi
from
Cape Coral, FL
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
University of Miami Sylvester at Deerfield Beach
mi
from
Deerfield Beach, FL
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
University of Miami Sylvester at Deerfield Beach
mi
from
Deerfield Beach, FL
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
mi
from
Englewood, FL
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
mi
from
Englewood, FL
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
mi
from
Fort Myers, FL
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
University of Miami Hospital and Clinics
mi
from
Miami, FL
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
University of Miami Hospital and Clinics
mi
from
Miami, FL
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
mi
from
Naples, FL
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
mi
from
Naples, FL
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Orlando Regional Medical Center
mi
from
Orlando, FL
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Orlando Regional Medical Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
mi
from
Port Charlotte, FL
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
mi
from
Sarasota, FL
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
mi
from
Sarasota, FL
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
mi
from
Venice, FL
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
mi
from
Venice, FL
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Peachtree Hematology-Oncology Consultants
mi
from
Atlanta, GA
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Peachtree Hematology-Oncology Consultants
mi
from
Atlanta, GA
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Chattanooga Oncology and Hematology Associates, PC
mi
from
Ringgold, GA
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Chattanooga Oncology and Hematology Associates, PC
mi
from
Ringgold, GA
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Mountain States Tumor Institute
mi
from
Boise, ID
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Mountain States Tumor Institute
mi
from
Boise, ID
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Mountain States Tumor Institute
mi
from
Fruitland, ID
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Mountain States Tumor Institute
mi
from
Fruitland, ID
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Mountain States Tumor Institute
mi
from
Meridian, ID
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Mountain States Tumor Institute
mi
from
Meridian, ID
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Mountain States Tumor Institute
mi
from
Nampa, ID
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Mountain States Tumor Institute
mi
from
Nampa, ID
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Mountain States Tumor Institute
mi
from
Twin Falls, ID
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Mountain States Tumor Institute
mi
from
Twin Falls, ID
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Loyola University of Chicago, Cardinal Bernardin Cancer Center
mi
from
Maywood, IL
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Loyola University of Chicago, Cardinal Bernardin Cancer Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Cental Indiana Cancer Centers
mi
from
Carmel, IN
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Cental Indiana Cancer Centers
mi
from
Carmel, IN
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Central Indiana Cancer Centers
mi
from
Fishers, IN
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Central Indiana Cancer Centers
mi
from
Fishers, IN
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Cental Indiana Cancer Centers
mi
from
Greenfield, IN
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Cental Indiana Cancer Centers
mi
from
Greenfield, IN
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Central Indiana Cancer Centers
mi
from
Indianapolis, IN
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Central Indiana Cancer Centers
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Karmanos Cancer Institute
mi
from
Detroit, MI
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Weisberg Cancer Treatment Center
mi
from
Farmington Hills, MI
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Weisberg Cancer Treatment Center
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Missouri Cancer Associates
mi
from
Columbia, MO
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Missouri Cancer Associates
mi
from
Columbia, MO
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
St. John's Mercy Medical Center
mi
from
Washington, MO
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
St. John's Mercy Medical Center
mi
from
Washington, MO
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Henderson, NV
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Henderson, NV
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Nevada Cancer Institute
mi
from
Las Vegas, NV
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Nevada Cancer Institute
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
The Cancer Center at Hackensack University Medical Center - The Hillcrest Building
mi
from
Hackensack, NJ
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
The Cancer Center at Hackensack University Medical Center - The Hillcrest Building
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
The Cancer Center, Hackensack University Medical Center
mi
from
Hackensack, NJ
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
The Cancer Center, Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials